Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00141271
Other study ID # A1281136
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 2005
Est. completion date February 2008

Study information

Verified date March 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.


Recruitment information / eligibility

Status Completed
Enrollment 536
Est. completion date February 2008
Est. primary completion date February 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in Diagnostic and Statistical Manual (of Mental Disorders) - Fourth Edition - Text Revision (DSM-IV-TR) (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI) Exclusion Criteria: - Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder not otherwise specified (298.9). - Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Geodon (Ziprasidone)
Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
Geodon (Ziprasidone)
Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
Placebo
Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial

Locations

Country Name City State
United States Pfizer Investigational Site Arlington Virginia
United States Pfizer Investigational Site Atlanta Georgia
United States Pfizer Investigational Site Bellaire Texas
United States Pfizer Investigational Site Birmingham Alabama
United States Pfizer Investigational Site Boston Massachusetts
United States Pfizer Investigational Site Charleston South Carolina
United States Pfizer Investigational Site Cincinnati Ohio
United States Pfizer Investigational Site Clementon New Jersey
United States Pfizer Investigational Site Cleveland Ohio
United States Pfizer Investigational Site Cleveland Ohio
United States Pfizer Investigational Site Columbia South Carolina
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site Dana Point California
United States Pfizer Investigational Site DeSoto Texas
United States Pfizer Investigational Site Falls Church Virginia
United States Pfizer Investigational Site Flowood Mississippi
United States Pfizer Investigational Site Fort Lauderdale Florida
United States Pfizer Investigational Site Gainesville Florida
United States Pfizer Investigational Site Galveston Texas
United States Pfizer Investigational Site Greenwood Indiana
United States Pfizer Investigational Site Hialeah Florida
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Irving Texas
United States Pfizer Investigational Site Jacksonville Florida
United States Pfizer Investigational Site Kirkland Washington
United States Pfizer Investigational Site La Mesa California
United States Pfizer Investigational Site Lafayette Indiana
United States Pfizer Investigational Site Laguna Hills California
United States Pfizer Investigational Site Las Vegas Nevada
United States Pfizer Investigational Site Mayfield Ohio
United States Pfizer Investigational Site Maywood Illinois
United States Pfizer Investigational Site Memphis Tennessee
United States Pfizer Investigational Site Milwaukee Wisconsin
United States Pfizer Investigational Site Milwaukee Wisconsin
United States Pfizer Investigational Site Minneapolis Minnesota
United States Pfizer Investigational Site Naperville Illinois
United States Pfizer Investigational Site Nashville Tennessee
United States Pfizer Investigational Site New Orleans Louisiana
United States Pfizer Investigational Site New York New York
United States Pfizer Investigational Site North Miami Florida
United States Pfizer Investigational Site Oceanside California
United States Pfizer Investigational Site Oklahoma City Oklahoma
United States Pfizer Investigational Site Omaha Nebraska
United States Pfizer Investigational Site Orange California
United States Pfizer Investigational Site Orlando Florida
United States Pfizer Investigational Site Philadelphia Pennsylvania
United States Pfizer Investigational Site Philadelphia Pennsylvania
United States Pfizer Investigational Site Pittsburgh Pennsylvania
United States Pfizer Investigational Site Plano Texas
United States Pfizer Investigational Site Prarie Village Kansas
United States Pfizer Investigational Site Richardson Texas
United States Pfizer Investigational Site Richmond Virginia
United States Pfizer Investigational Site Richmond Virginia
United States Pfizer Investigational Site Saint Louis Missouri
United States Pfizer Investigational Site Saint Louis Missouri
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site San Diego California
United States Pfizer Investigational Site San Diego California
United States Pfizer Investigational Site Santa Ana California
United States Pfizer Investigational Site Schaumburg Illinois
United States Pfizer Investigational Site Shreveport Louisiana
United States Pfizer Investigational Site Shreveport Louisiana
United States Pfizer Investigational Site Staten Island New York
United States Pfizer Investigational Site Toms River New Jersey
United States Pfizer Investigational Site Torrance California
United States Pfizer Investigational Site Virginia Beach Virginia
United States Pfizer Investigational Site West Allis Wisconsin
United States Pfizer Investigational Site Wichita Falls Texas
United States Pfizer Investigational Site Winter Park Florida
United States Pfizer Investigational Site Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. MADRS is 10-item instrument measuring depression; scale 0(Normal) and 6(most abnormal). Total possible score is 0 - 60. Baseline to 6 weeks
Secondary Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score Participants with MADRS Total Score greater or equal to 50 percent decrease from baseline responded yes; others responded no. Endpoint is last observation carried forward (LOCF) among Week 1 - Week 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6 (most abnormal). Total possible score is 0 - 60 Baseline to 6 weeks
Secondary Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score Participants with greater than or equal to 50 percent decrease from baseline in HAMD-17 total score responded yes; others responded no. Endpoint is LOCF endpoint among Week 1 - 6; Total score is first 17 items of HAM-D 25: measures range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52. Baseline to 6 weeks
Secondary Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF) Change is observed value at endpoint minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 - 6; GAF is used to assess global psychological, social, & occupational functioning; 100=normal and 0=greatest abnormality Baseline, 6 Weeks LOCF
Secondary Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12 Response was Yes if MADRS Total Score was less than, equal to 12, if not, response was no. Endpoint is LOCF endpoint among Week 1 through 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6(most abnormal) Baseline to 6 weeks
Secondary Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7 Response was yes when HAM-D 17 total score was less than or equal to 7 , if not, response was no. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25,which measures the range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52. Baseline to 6 weeks
Secondary Change in Hamilton Depression (HAM-D 17) Total Score Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25, which measures the range of depressive symptoms patient currently experiencing; scale 0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme. Total possible score 0 - 52. Baseline to 6 weeks
Secondary Change in Hamilton Anxiety Rating (HAM-A) Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. HAM-A is a 14-item scale: rates intensity of psychic anxiety and somatic anxiety on a 5-point severity scale (range: 0=not present to 4=very severe). Total possible score is 0 - 56. Baseline to 6 weeks
Secondary Change in Total Score of Young Mania Rating Scale (YMRS) Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. YMRS: 11 item instrument with scale 0 to 4 for 7 items and 0 to 8 for 4 items; 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60. Baseline to 6 weeks
Secondary Change in Assessment of Global Clinical Severity of Symptoms (CGI-S) Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-S measures severity of patient's mental illness. Scale range: 0 = not assessed, 1 = normal, 7 = among most extremely ill Baseline to 6 weeks
Secondary Change in Global Clinical Improvement of Symptoms (CGI -I) Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-I is an instrument for Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse Baseline to 6 weeks
Secondary Change in Total Score in Hamilton Depression (HAM-D 25) Change: observed value at each visit minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 through Week 6. HAM-D 25: measures the range of depressive symptoms experienced. 25 Items with Scale range:0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme.Total possible score is 0 - 72. Baseline to 6 Weeks
Secondary Response as Measured by CGI-I Score Less Than or Equal to 2 Response each week was yes if CGI-I score less than or equal to 2 (much or very much improved), if not, response was no; Endpoint is LOCF endpoint among Week 1 through Week 6. CGI-I is a Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse Week 1 through Week 6 (endpoint)
Secondary Change in Sheehan Disability Scale (SDS) Total Score at Endpoint Observed value each visit minus baseline value. Endpoint is LOCF Week 1 through Week 6. SDS: patient rated measure of disability and impairment in 3 items: work/school, social life, family life/home responsibilities:0(no disruption)- 10(extreme disruption). Total possible is 30. Baseline to Week 6
Secondary Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint Change is observed value at each visit minus baseline value. LOCF endpoint among Week 1 through Week 6. Q-LES-Q: 16-item instrument for patients assessment of his/her quality of life; overall level of satisfaction scale 1=very poor to 5=Very good (1 item re medication can be blank). Total possible score 15 - 80 Baseline to 6 Weeks
Secondary Change in Bech Melancholia Score Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Bech Melancholia is the sum of Scores on 6 Items pertaining to melancholia within Hamilton Depression Rating Scale (HAM-D). Scale 0 to 4, higher scores reflecting greater severity;Total possible 0 - 24. Baseline to 6 Weeks
Secondary Change in Anxiety/Somatizations Factor Total Score Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores on 6 Items measuring anxiety/somatization within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4, higher scores reflecting greater severity. Total possible 0 - 24. Baseline to 6 Weeks
Secondary Change in Retardation Factor Scores Change is observed value at each visit minus baseline value. This instrument = sum of Scores of 4 items on retardation within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 16. Baseline to 6 Weeks
Secondary Change in Sleep Disturbance Factor Score Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores of 3 items on sleep disturbance within Hamilton Depression Rating Scale (HAM-D). Scale range 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 12. Baseline to 6 weeks
Secondary Change in Verbal Memory Trial Performance Total Score at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is part of Brief Assessment of Cognition and measures recall of 15 words repeated 5 times. Range 0-75 words, higher number reflects better recall. Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition measuring immediate recall of 15 emotional words; higher number of words is better recall. Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument measures immediate recall of 15 non-emotional words (List 1); higher number of words is better recall. Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is in Brief Assessment of Cognition and measures immediate recall of 15 emotional words (List 2); higher number of words is better recall Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 2); higher number of words is better recall Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 emotional words (List 3); higher number of words is better recall Baseline to Week 6 LOCF
Secondary Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 3); higher number of words is better recall Baseline to Week 6 LOCF
Secondary Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 non-emotional words; higher number of words is better recall Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 emotional words; higher number of words is better recall Baseline to 6 Weeks LOCF
Secondary Change in Digit Sequencing Task at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which patient sequences digits from lowest to highest. Range of number of correct responses (0-28); higher numbers show better digit sequencing and greater cognition. Baseline to 6 Weeks LOCF
Secondary Change in Token Motor Task at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which a patient places as many of 100 tokens (2 at a time) into a container as they can within 60 seconds. The higher number of tokens placed = patient is better at motor tasks Baseline to 6 Weeks LOCF
Secondary Change in Verbal Fluency in Naming Categories at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition.Patients are given 60 seconds to name as many words as possible within a given category. The more words named=better cognition. Baseline to 6 Weeks LOCF
Secondary Change in Verbal Fluency Controlled Word Association at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. Patients given 60 seconds to generate as many words as possible that begin with a given letter; better verbal fluency = more words Baseline to 6 Weeks LOCF
Secondary Change in Symbol Coding at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. For 90 seconds, Patient writes numerals 1-9 as matched to symbols. Range 0 to 110 with higher totals = better cognition. Baseline to 6 Weeks LOCF
Secondary Change in Tower of London Test at Endpoint Change is observed value at each visit minus baseline value. Endpoint: LOCF endpoint among Week 1 through Week 6. Brief Assessment of Cognition: subjects asked to arrange balls in 2 pictures so they are identical and give the total number of ball movements to reach this arrangment. Range: 0-22; more correct = better cognition. Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition in which the number of correct emotional words in delayed recognition is measured. Range 0-75 with higher numbers showing better cognition. Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition which measures number of correct emotional word's false alarms (during delayed recognition). Higher number = better cognition Baseline to 6 Weeks LOCF
Secondary Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of Non-Emotional Words (Delayed Recognition); higher number of words = better cognition Baseline to Week 6 LOCF
Secondary Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of correct non-eEmotional word's false alarms(at delayed recognition). Higher number of words = greater cognition Baseline to Week 6 LOCF
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study